71 results on '"Rizzo, J. Douglas"'
Search Results
2. First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation
- Author
-
Martin, Paul J., Rizzo, J. Douglas, Wingard, John R., Ballen, Karen, Curtin, Peter T., Cutler, Corey, Litzow, Mark R., Nieto, Yago, Savani, Bipin N., Schriber, Jeffrey R., Shaughnessy, Paul J., Wall, Donna A., and Carpenter, Paul A.
- Subjects
- *
GRAFT versus host disease , *IMMUNOSUPPRESSIVE agents , *CELL transplantation , *METHYLPREDNISOLONE , *GLUCOCORTICOIDS , *BONE marrow transplantation , *IMMUNOPHARMACOLOGY - Abstract
Despite prophylaxis with immunosuppressive agents or a variety of other approaches, many patients suffer from acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation. Although consensus has emerged supporting the use of high-dose methylprednisolone or prednisone for initial treatment of aGVHD, practices differ among centers with respect to the initial glucocorticoid dose, the use of additional immunosuppressive agents, and the approach to withdrawal of treatment after initial improvement. Despite many studies, practices vary considerably with respect to the selection of agents for treatment of glucocorticoid-resistant or refractory GVHD. Investigators and clinicians have recognized the lack of progress and lamented the absence of an accepted standard of care for secondary treatment of aGVHD. The American Society of Blood and Marrow Transplantation has developed recommendations for treatment of aGVHD to be considered by care providers, based on a comprehensive and critical review of published reports. Because the literature provides little basis for a definitive guideline, this review also provides a framework for the interpretation of previous results and the design of future studies. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
3. Recommended Screening and Preventive Practices for Long-Term Survivors after Hematopoietic Cell Transplantation
- Author
-
Majhail, Navneet S., Rizzo, J. Douglas, Lee, Stephanie J., Aljurf, Mahmoud, Atsuta, Yoshiko, Bonfim, Carmem, Burns, Linda J., Chaudhri, Naeem, Davies, Stella, Okamoto, Shinichiro, Seber, Adriana, Socie, Gerard, Szer, Jeff, Van Lint, Maria Teresa, Wingard, John R., and Tichelli, Andre
- Subjects
- *
MEDICAL screening , *HEMATOPOIETIC stem cells , *STEM cell transplantation , *OLDER patients , *CLINICAL indications , *GUIDELINES , *COMPLICATIONS from organ transplantation - Abstract
Advances in hematopoietic cell transplantation (HCT) technology and supportive care techniques have led to improvements in long-term survival after HCT. Emerging indications for transplantation, introduction of newer graft sources (eg, umbilical cord blood) and transplantation of older patients using less intense conditioning regimens have also contributed to an increase in the number of HCT survivors. These survivors are at risk for developing late complications secondary to pre-, peri-, and posttransplantation exposures and risk factors. Guidelines for screening and preventive practices for HCT survivors were published in 2006. An international group of transplantation experts was convened in 2011 to review contemporary literature and update the recommendations while considering the changing practice of transplantation and international applicability of these guidelines. This review provides the updated recommendations for screening and preventive practices for pediatric and adult survivors of autologous and allogeneic HCT. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
4. The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myeloid Leukemia in Children: An Evidence-Based Review
- Author
-
Oliansky, Denise M., Rizzo, J. Douglas, Aplan, Peter D., Arceci, Robert J., Leone, Louis, Ravindranath, Yaddanapudi, Sanders, Jean E., Smith, Franklin O., Wilmot, Fiona, McCarthy, Philip L., and Hahn, Theresa
- Subjects
- *
HEMATOPOIETIC stem cells , *ACUTE myeloid leukemia , *EVIDENCE-based medicine , *GRAFT versus host disease , *CYTOGENETICS - Abstract
Abstract: Clinical research examining the role of hematopoietic stem cell transplantation (SCT) in the therapy of acute myeloid leukemia (AML) in children is presented and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the published literature and for grading the quality and strength of the evidence and the strength of the treatment recommendations. Treatment recommendations based on the evidence are presented in the table entitled “Summary of Treatment Recommendations Made by the Expert Panel for Pediatric Acute Myeloid Leukemia” and were reached unanimously by a panel of experts in AML. The identified priority areas of needed future research in pediatric AML include: What is the role of risk group stratification, including the role of cytogenetics, in selection of patients for allogeneic SCT, especially those in first CR? What is the appropriate timing and use of alternative donor SCT, given that matched unrelated donor SCT appears to yield outcomes equivalent to matched related donor SCT? What is the role of reduced intensity SCT (including the use of fludarabine-based preparative regimens) and/or other immunomodulatory approaches to maximize the graft-versus-leukemic effect? and What is the role of biologically targeted agents (ie, tyrosine kinase inhibitors, farnesyl transferase inhibitors, Flt-3 inhibitors, etc) in the treatment of AML, including induction, consolidation, conditioning regimens, and after SCT? [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
5. Recommended Screening and Preventive Practices for Long-term Survivors after Hematopoietic Cell Transplantation: Joint Recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation
- Author
-
Rizzo, J. Douglas, Wingard, John R., Tichelli, Andre, Lee, Stephanie J., Van Lint, Maria Teresa, Burns, Linda J., Davies, Stella M., Ferrara, James L.M., and Socié, Gérard
- Subjects
- *
BONE marrow transplant complications , *HEMATOPOIETIC system , *IMMUNE system , *PUBLIC health , *MEDICAL care - Abstract
Abstract: More than 40000 hematopoietic cell transplants (HCTs) are performed worldwide each year. With improvements in transplant technology, larger numbers of transplant recipients survive free of the disease for which they were transplanted. However, there are late complications that can cause substantial morbidity. Many survivors are no longer under the care of transplant centers, and many community health care providers may be unfamiliar with health matters relevant to HCT. The Center for International Blood and Marrow Transplant Research (CIBMTR), European Group for Blood and Marrow Transplantation (EBMT), and American Society for Bone Marrow Transplantation (ASBMT) have developed these recommendations to offer care providers suggested screening and prevention practices for autologous and allogeneic HCT survivors. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
6. 286 - Propranolol Inhibits Stress-Related Gene Expression Profiles Associated with Adverse Clinical Outcomes in Autologous Hematopoietic Cell Transplantation Recipients.
- Author
-
Knight, Jennifer, Rizzo, J. Douglas, Hari, Parameswaran, Kerswill, Stephanie, D'Souza, Anita, Logan, Brent R., Hamadani, Mehdi, Chhabra, Saurabh, Dhakal, Binod, Shah, Nirav, and Cole, Steve
- Published
- 2018
- Full Text
- View/download PDF
7. 8 - Genomic Mechanisms of SES-Related Outcome Disparities in Hematopoietic Cell Transplantation.
- Author
-
Knight, Jennifer, Rizzo, J. Douglas, Wang, Tao, He, Naya, Logan, Brent R., Spellman, Stephen R., Lee, Stephanie J., and Cole, Steve
- Published
- 2018
- Full Text
- View/download PDF
8. The Evolution of the Evidence-Based Review: Evaluating the Science Enhances the Art of Medicine—Statement of the Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplantation
- Author
-
Jones, Roy, Nieto, Yago, Rizzo, J. Douglas, Wall, Donna, Wingard, John R., McCarthy, Philip, and Hahn, Theresa
- Published
- 2005
- Full Text
- View/download PDF
9. Optimistic expectations and survival after hematopoietic stem cell transplantation
- Author
-
Lee, Stephanie J., Loberiza, Fausto R., Rizzo, J. Douglas, Soiffer, Robert J., Antin, Joseph H., and Weeks, Jane C.
- Subjects
- *
OPTIMISM , *MEDICAL consultants , *HEMATOPOIESIS - Abstract
An optimistic attitude is hypothesized to be beneficial when facing a life-threatening medical condition. However, the actual relationship of high expectations for treatment success and medical outcome is controversial. Using a prospective cohort of 313 autologous and allogeneic hematopoietic stem cell transplant patients enrolled July 1996 through November 1999, we tested whether patient-reported expectations before transplantation were associated with survival and quality of life following the procedure. Before transplantation, patients with higher expectations that the transplant procedure would go well had better mental and emotional functioning, but similar physical status and medical condition to patients with less optimistic expectations. In the first 2 months after transplantation, optimistic expectations were associated with better survival (92% v 84%; relative risk for mortality 0.45, 95% confidence interval 0.22–0.92; P=.03) controlling for other physical and mental characteristics. However, by 6 months posttransplantation, survival and quality of life were indistinguishable between patients with initially higher and lower expectations. Our data suggest an association between more optimistic expectations and early survival following hematopoietic stem cell transplantation, but this association is not present by 6 months posttransplantation. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
10. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States.
- Author
-
D'Souza, Anita, Fretham, Caitrin, Lee, Stephanie J, Arora, Mukta, Brunner, Janet, Chhabra, Saurabh, Devine, Steven, Eapen, Mary, Hamadani, Mehdi, Hari, Parameswaran, Pasquini, Marcelo C, Perez, Waleska, Phelan, Rachel A, Riches, Marcie L, Rizzo, J Douglas, Saber, Wael, Shaw, Bronwen E, Spellman, Stephen R, Steinert, Patricia, and Weisdorf, Daniel J
- Subjects
- *
CELL transplantation , *ACUTE myeloid leukemia , *HEMATOPOIETIC system , *AUTOTRANSPLANTATION , *MYELODYSPLASTIC syndromes , *PROGNOSIS - Abstract
• We summarize hematopoietic cell transplantation activity in the United States in 2018. • Key findings include fewer autologous transplantations performed for non-Hodgkin lymphoma and increasing numbers of haploidentical transplantations. • There is a continuing increase in transplantation activity in adults age >70 years. Hematopoietic cell transplantation (HCT) is a well-established treatment to control and/or cure many malignant and nonmalignant diseases involving the hematopoietic system and some solid tumors. We report information about HCT procedures performed in the United States in 2018 and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Overall, compared with 2017, the number of allogeneic HCTs performed in the United States increased by 1%, and the number of autologous HCTs decreased by 5%. Key findings are fewer autologous HCTs performed for non-Hodgkin lymphoma and increasing numbers of haploidentical HCTs, nearly all of which use post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. There is a continuing increase in HCT in adults age >70 years, particularly for acute myelogenous leukemia and myelodysplastic syndromes. Survival rates by disease, disease stage, donor type, and age are presented. This report, prepared annually by the CIBMTR, provides a snapshot of current transplant activity in the United States. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia.
- Author
-
Eapen, Mary, Zhang, Mei-Jie, Tang, Xiao-Ying, Lee, Stephanie J., Fei, Ming-Wei, Wang, Hai-lin, Hebert, Kyle M., Arora, Mukta, Chhabra, Saurabh, Devine, Steven M., Hamadani, Mehdi, D'Souza, Anita, Pasquini, Marcelo C., Phelan, Rachel, Rizzo, J. Douglas, Saber, Wael, Shaw, Bronwen E., Weisdorf, Daniel J, and Horowitz, Mary M.
- Subjects
- *
APLASTIC anemia , *CELL transplantation , *ABO blood group system , *BLOOD group incompatibility , *COVID-19 pandemic , *GRAFT versus host disease - Abstract
With the COVID-19 pandemic and the ensuing barriers to the collection and transport of donor cells, it is often necessary to collect and cryopreserve grafts before initiation of transplantation conditioning. The effect on transplantation outcomes in nonmalignant disease is unknown. This analysis examined the effect of cryopreservation of related and unrelated donor grafts for transplantation for severe aplastic anemia in the United States during 2013 to 2019. Included are 52 recipients of cryopreserved grafts who were matched for age, donor type, and graft type to 194 recipients who received noncryopreserved grafts. Marginal Cox regression models were built to study the effect of cryopreservation and other risk factors associated with outcomes. We recorded higher 1-year rates of graft failure (hazard ratio [HR], 2.26; 95% confidence interval, 1.17 to 4.35; P =.01) and of 1-year overall mortality (HR, 3.13; 95% CI, 1.60 to 6.11; P =.0008) after transplantation of cryopreserved compared with noncryopreserved grafts, with adjustment for sex, performance score, comorbidity, cytomegalovirus serostatus, and ABO blood group match. The incidence of acute and chronic graft-versus-host disease did not differ between the 2 groups. Adjusted probabilities of 1-year survival were 73% (95% CI, 60% to 84%) in the cryopreserved graft group and 91% (95% CI, 86% to 94%) in the noncryopreserved graft group. These data support the use of noncryopreserved grafts whenever possible in patients with severe aplastic anemia. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results.
- Author
-
Pulsipher, Michael A., Logan, Brent R., Kiefer, Deidre M., Chitphakdithai, Pintip, Riches, Marcie L., Rizzo, J. Douglas, Anderlini, Paolo, Leitman, Susan F., Varni, James W., Kobusingye, Hati, Besser, RaeAnne M., Miller, John P., Drexler, Rebecca J., Abdel-Mageed, Aly, Ahmed, Ibrahim A., Ball, Edward D., Bolwell, Brian J., Bunin, Nancy J., Cheerva, Alexandra, and Delgado, David C.
- Subjects
- *
BONE marrow , *FEMALES , *OLD age , *BLOOD cells , *POSTOPERATIVE pain - Abstract
• Children commonly report pain (71%) and symptoms (59%) at 24 to 48 hours after bone marrow (BM) donation. • Older age and female sex are associated with higher levels of pain peri-BM donation. • Females age 13 to 17 years are at increased risk for grade 2 to 4 pain at 1 year after BM donation. • More than 20% of donors age 13 to 17 do not return to baseline pain level at 1 year after BM donation. Although donation of bone marrow (BM) or peripheral blood stem cells (PBSCs) from children to family members undergoing allogeneic transplantation are well-established procedures, studies detailing levels of pain, symptoms, and long-term recovery are lacking. To address this lack, we prospectively enrolled 294 donors age <18 years at 25 pediatric transplantation centers in North America, assessing them predonation, peridonation, and at 1 month, 6 months, and 1 year postdonation. We noted that 71% of children reported pain and 59% reported other symptoms peridonation, with resolution to 14% and 12% at 1 month postdonation. Both older age (age 13 to 17 years versus younger) and female sex were associated with higher levels of pain peridonation, with the highest rates in older females (57% with grade 2-4 pain and 17% with grade 3-4 pain). Multivariate analyses showed a 4-fold increase in risk for older females compared with males age <13 years (P <.001). At 1 year, 11% of 13- to 17-year-old females reported grade 2-4 pain, compared with 3% of males age 13 to 17 years, 0% of females age <13 years, and 1% of males age <13 years (P =.01). Males and females age 13 to 17 years failed to return to predonation pain levels at 1 year 22% and 23% of the time, respectively, compared with 3% and 10% in males and females age <13 years (P =.002). Our data show that females age 13 to 17 years are at increased risk of grade 2-4 pain at 1 year and >20% of females and males age 13 to 17 years do not return to baseline pain levels by 1 year after BM donation. Studies aimed at decreasing symptoms and improving recovery in older children are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
13. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting.
- Author
-
Guru Murthy, Guru Subramanian, Hari, Parameswaran N., Szabo, Aniko, Pasquini, Marcelo, Narra, Ravi, Khan, Muhammad, Abedin, Sameem, Chhabra, Saurabh, Dhakal, Binod, D'Souza, Anita, Drobyski, William R., Rizzo, J. Douglas, Runaas, Lyndsey, Shah, Nirav N., Shaw, Bronwen, Saber, Wael, Fenske, Timothy, and Hamadani, Mehdi
- Subjects
- *
CELL transplantation , *GRAFT versus host disease , *PROGRESSION-free survival , *HEMATOLOGIC malignancies , *PARENTERAL feeding , *NATALIZUMAB , *ALEMTUZUMAB - Abstract
Highlights • Outpatient reduced-intensity allogeneic transplant is safe and feasible. • Its outcomes are comparable with similar transplants done in the inpatient setting. • Outpatient transplants had significantly lower charges than inpatient transplants. Abstract Allogeneic hematopoietic cell transplantation (allo-HCT) with reduced-intensity conditioning (RIC) is commonly performed as an inpatient procedure. The feasibility and outcomes of RIC allo-HCT in the outpatient setting is not known. We performed a single-center retrospective cohort study of patients aged ≥ 18years with hematologic malignancies who underwent RIC allo-HCT either in the inpatient or outpatient setting. Donor types included HLA-matched sibling and well-matched unrelated donors. The objectives were to compare the survival, complications, charges, and incidences of relapse, nonrelapse mortality (NRM), and acute and chronic graft-versus-host disease (GVHD) between the 2 groups. Between 2014 and 2017, 151 eligible patients were included, with 116 undergoing RIC allo-HCT in the inpatient setting and 35 patients undergoing RIC allo-HCT in the outpatient setting. Baseline characteristics were comparable between the 2 groups except for a higher proportion of patients with myeloma in the outpatient cohort (inpatient 15.5% versus outpatient 37.1%). The cumulative incidence of grades II to IV acute GVHD (inpatient 25.2% versus outpatient 25.7%), grades III to IV acute GVHD (inpatient 10.4% versus outpatient 8.5%), chronic GVHD (inpatient 38.3% versus outpatient 51.6%), NRM at 1 year (inpatient 10.8% versus outpatient 3.2%), and relapse (inpatient 24.8% versus outpatient 33.2%) did not significantly differ between the 2 cohorts. One-year progression-free survival (inpatient 64.4% versus outpatient 63.6%, P =.39) and overall survival (inpatient 73.8% versus outpatient 82.8%, P =.93) were also not significantly different between the 2 groups. The proportion of patients who developed neutropenic fever (inpatient 25.8% versus outpatient 8.5%, P =.03) and mucositis (inpatient 50.8% versus outpatient 8.5%, P <.001) and who required total parenteral nutrition (inpatient 20.6% versus outpatient 5.7%, P =.04) were more frequent in the inpatient cohort. About 51.5% of the outpatient cohort never required hospital admission in the first 100days. Outpatient HCT resulted in significantly lower charges than inpatient HCT in the first 100days (median charges: inpatient $339,621 versus outpatient $247,334; P <.001). On multivariate analysis the site of the HCT (outpatient versus inpatient) was not a significant predictor of either overall or progression-free survival. Outpatient RIC allo-HCT is feasible and safe with daily outpatient evaluation and aggressive supportive care resulting in outcomes comparable with those who received the transplant in the inpatient setting. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study.
- Author
-
Pulsipher, Michael A., Logan, Brent R., Chitphakdithai, Pintip, Kiefer, Deidre M., Riches, Marcie L., Rizzo, J. Douglas, Anderlini, Paolo, Leitman, Susan F., Varni, James W., Kobusingye, Hati, Besser, RaeAnne M., Miller, John P., Drexler, Rebecca J., Abdel-Mageed, Aly, Ahmed, Ibrahim A., Akard, Luke P., Artz, Andrew S., Ball, Edward D., Bayer, Ruthee-Lu, and Bigelow, Carolyn
- Subjects
- *
HEMAPHERESIS , *STEM cell donors , *LEUKAPHERESIS , *BLOOD cells , *CHRONIC pain , *CELL transplantation , *STEM cells - Abstract
Highlights • Older PBSC donors have lower CD34+ yields, leading to higher volume collections. • Higher volume and number of collections lead to high rates of thrombocytopenia. • Younger PBSC donors have higher rates of acute pain and symptoms with PBSC collection. • Older PBSC donors have a higher rate of nonrecovery to baseline at 1 year. • Donors with comorbidities are at increased risk for pain and symptoms at 1 year. Abstract The development of reduced-intensity approaches for allogeneic hematopoietic cell transplantation has resulted in growing numbers of older related donors (RDs) of peripheral blood stem cells (PBSCs). The effects of age on donation efficacy, toxicity, and long-term recovery in RDs are poorly understood. To address this we analyzed hematologic variables, pain, donation-related symptoms, and recovery in 1211 PBSC RDs aged 18 to 79 enrolled in the Related Donor Safety Study. RDs aged > 60 had a lower median CD34+ level before apheresis compared with younger RDs (age > 60, 59 × 106/L; age 41 to 60, 81 × 106/L; age 18 to 40, 121 × 106/L; P <.001). This resulted in older donors undergoing more apheresis procedures (49% versus 30% ≥ 2 collections, P <.001) and higher collection volumes (52% versus 32% > 24 L, P <.001), leading to high percentages of donors aged > 60 with postcollection thrombocytopenia <50 × 109/L (26% and 57% after 2 and 3days of collection, respectively). RDs aged 18 to 40 had a higher risk of grades 2 to 4 pain and symptoms pericollection, but donors over age 40 had more persistent pain at 1, 6, and 12 months (odds ratio [OR], 1.7; P = 0.02) and a higher rate of nonrecovery to predonation levels (OR, 1.7; P =.01). Donors reporting comorbidities increased significantly with age, and those with comorbidities that would have led to deferral by National Marrow Donor Program unrelated donor standards had an increased risk for persistent grades 2 to 4 pain (OR, 2.41; P <.001) and failure to recover to predonation baseline for other symptoms (OR, 2.34; P =.004). This information should be used in counseling RDs regarding risk and can assist in developing practice approaches aimed at improving the RD experience for high-risk individuals. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
15. Tailoring a Survivorship Care Plan: Patient and Provider Preferences for Recipients of Hematopoietic Cell Transplantation.
- Author
-
Denzen, Ellen M., Preussler, Jaime M., Murphy, Elizabeth A., Baker, K. Scott, Burns, Linda J., Foster, Jackie, Idossa, Lensa, Moore, Heather K., Payton, Tammy J., Haven, Darlene, Jahagirdar, Balkrishna, Kamani, Naynesh, Rizzo, J. Douglas, Salazar, Lizette, Schatz, Barry A., Syrjala, Karen L., Wingard, John R., and Majhail, Navneet S.
- Subjects
- *
CELL transplantation , *MEDICAL protocols , *MEDICAL personnel , *MENTAL health , *SOCIAL workers - Abstract
Highlights • An individualized survivorship care plan for transplantation survivors was developed. • The plan was tailored to patient and provider preferences. • This study highlights the need for a care plan to facilitate survivorship care. ABSTRACT This study aimed to develop a survivorship care plan (SCP) that can be individualized to facilitate long-term follow-up care of hematopoietic cell transplantation (HCT) survivors. A sample SCP was developed that included 2 documents: a treatment summary and preventive care recommendations that combined data on treatment exposures routinely submitted by HCT centers to the Center for International Blood and Marrow Transplant Research (CIBMTR) with long-term follow-up guidelines. Focus groups were conducted by phone to characterize the critical patient-centered elements of the SCP. Focus group eligibility criteria included (1) adult patients >1 year post-HCT and their caregivers (3 groups; n = 22), (2) HCT physicians and advanced practice providers (APPs) (2 groups; n = 14), (3) HCT nurses and social workers (4 groups; n = 17), and (4) community health care professionals (3 groups; n = 24). Transcripts were analyzed for saturation of key themes using NVivo 10 software. Patients and caregivers suggested combining the treatment summary and care guidelines into a single document. They also requested sections on sexual and emotional health and the immune system. Providers wanted the treatment summary to focus only on what they absolutely must know. Themes were similar across healthcare professionals, although screening for psychosocial issues was emphasized more by the nurses and social workers. All preferred to receive the SCP electronically; however, hardcopy was considered necessary for some patients. All felt that the SCP would facilitate appropriate post-HCT care. This study highlights the need for an SCP instrument to facilitate HCT survivorship care. Furthermore, it demonstrates the feasibility and value of engaging HCT recipients, caregivers, and providers in developing an SCP. Their feedback was incorporated into a final SCP that was subsequently tested in a randomized trial. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
16. Peripheral Blood Grafts for T Cell–Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome.
- Author
-
Raj, Renju V., Hamadani, Mehdi, Szabo, Aniko, Pasquini, Marcelo C., Shah, Nirav N., Drobyski, William R., Shaw, Bronwen E., Saber, Wael, Rizzo, J. Douglas, Jerkins, James, Fenske, Timothy S., D'souza, Anita, Dhakal, Binod, Zhang, Chao, Konings, Steve, Hari, Parameswaran N., and Chhabra, Saurabh
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *GRAFT versus host disease , *T cells , *CYTOKINES , *CYCLOPHOSPHAMIDE - Abstract
T cell–replete post-transplant cyclophosphamide (PTCy)-based protocols have led to increasing use of haploidentical allogeneic hematopoietic cell transplantation (haploHCT). With this approach, bidirectional alloreactivity causing nonengraftment or severe graft-versus-host disease (GVHD) is no a longer major barrier to haploHCT. PTCy eliminates alloreactive lymphocytes but spares CD34 + stem cells and regulatory T lymphocytes, resulting in reliable hematopoietic recovery with relatively low incidence of GVHD. The immediate post-haploHCT course, usually before PTCy administration, is often complicated by cytokine release syndrome (CRS). The predictors of CRS and its effect on outcomes post-transplant have not been fully ascertained. We analyzed the outcomes of 66 patients who received haploHCT at our institution. Using published CRS criteria we identified 48 patients who developed CRS. In multivariate analysis peripheral blood grafts were significantly associated with grade ≥ 2 CRS, compared with bone marrow. Grade ≥ 2 CRS (compared with grade < 2) was not associated with differences in overall survival or nonrelapse mortality. Severe CRS was associated with a statistically nonsignificant trend toward higher incidences of grades III to IV acute GVHD, especially in the context of peripheral blood grafts. CRS is a common complication after T cell–replete peripheral blood haploHCT, but post-transplant survival outcomes may not be affected in those with severe CRS. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
17. Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome.
- Author
-
Thompson, Jonathan, D'Souza, Anita, Fenske, Timothy, Hamadani, Mehdi, Hari, Parameswaran, Rizzo, J. Douglas, Pasquini, Marcelo, Saber, Wael, Shah, Nirav, Shaw, Bronwen E., Drobyski, William R., Yin, Ziyan, Banerjee, Anjishnu, and Shahir, Kaushik
- Subjects
- *
PNEUMONIA treatment , *ETANERCEPT , *HORMONE therapy , *CORTICOSTEROIDS , *HEMATOPOIETIC stem cell transplantation , *TUMOR necrosis factors , *DELAYED onset of disease , *THERAPEUTICS - Abstract
Idiopathic pneumonia syndrome (IPS) is a complication of allogeneic hematopoietic stem cell transplantation (HSCT) that typically occurs within the first 100 days after transplantation. Tumor necrosis factor α (TNF-α) has been shown to be a key mediator of IPS, and the TNF-α binding protein etanercept appeared to improve IPS outcomes in small retrospective and prospective studies. IPS also has been observed to occur later (>100 days) after HSCT; however, little is known about the disease course and whether a TNF-α–based therapeutic strategy is efficacious in these patients. To address this question, we performed a retrospective analysis of 23 patients who underwent HSCT between 2004 and 2016 at our institution who developed late-onset IPS and received treatment with etanercept and high-dose corticosteroids (CS). Ten of the 23 patients (43%) attained a complete clinical response to etanercept and CS. Responses were significantly more likely to occur in patients who did not require positive pressure ventilation at the time of diagnosis. Those who responded experienced a durable survival benefit, with a 2-year overall survival of 67%. In the 13 patients (57%) who did not respond to etanercept and CS, the median overall survival was only 13 days (range, 1 to 60 days). The difference in 2-year overall survival between responders and nonresponders was statistically significant (67% versus 0%; P < .001). These results indicate that late-onset IPS carries high mortality, but that treatment with etanercept and CS has activity and can result in long-term survival in some patients. Prompt diagnosis and early institution of therapy before the need for advanced respiratory support is critical for maximizing responses. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
18. Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation.
- Author
-
Kanate, Abraham S., Hari, Parameswaran N., Pasquini, Marcelo C., Visotcky, Alexis, Ahn, Kwang W., Boyd, Jennifer, Guru Murthy, Guru Subramanian, Rizzo, J. Douglas, Saber, Wael, Drobyski, William, Michaelis, Laura, Atallah, Ehab, Carlson, Karen S., D'Souza, Anita, Fenske, Timothy S., Cumpston, Aaron, Bunner, Pamela, Craig, Michael, Horowitz, Mary M., and Hamadani, Mehdi
- Subjects
- *
ATORVASTATIN , *HEMATOPOIETIC stem cell transplantation , *GRAFT versus host disease , *IMMUNOREGULATION , *PREVENTIVE medicine , *THERAPEUTICS - Abstract
Atorvastatin administration to both the donors and recipients of matched related donor (MRD) allogeneic hematopoietic cell transplantation (allo-HCT) as acute graft-versus-host disease (GVHD) prophylaxis has been shown to be safe and effective. However, its efficacy as acute GVHD prophylaxis when given only to allo-HCT recipients is unknown. We conducted a phase II study to evaluate the safety and efficacy of atorvastatin-based acute GVHD prophylaxis given only to the recipients of MRD (n = 30) or matched unrelated donor (MUD) (n = 39) allo-HCT, enrolled in 2 separate cohorts. Atorvastatin (40 mg/day) was administered along with standard GVHD prophylaxis consisting of tacrolimus and methotrexate. All patients were evaluable for acute GVHD. The cumulative incidences of grade II to IV acute GVHD at day +100 in the MRD and MUD cohorts were 9.9% (95% confidence interval [CI], 0 to 20%) and 29.6% (95% CI,15.6% to 43.6%), respectively. The cumulative incidences of grade III and IV acute GVHD at day +100 in the MRD and MUD cohorts were 3.4% (95% CI, 0 to 9.7%) and 18.3% (95% CI, 6.3% to 30.4%), respectively. The corresponding rates of moderate/severe chronic GVHD at 1 year were 28.1% (95% CI, 11% to 45.2%) and 38.9% (95% CI, 20.9% to 57%), respectively. In the MRD cohort, the 1-year nonrelapse mortality, relapse rate, progression-free survival, and overall survival were 6.7% (95% CI, 0 to 15.4%), 43.3% (95% CI, 24.9% to 61.7%), 50% (95% CI, 32.1% to 67.9%), and 66.7% (95% CI, 49.8% to 83.6%), respectively. The respective figures for the MUD cohort were 10.3% (95% CI, 8% to 19.7%), 20.5% (95% CI, 7.9% to 33.1%), 69.2% (95% CI, 54.7% to 83.7%), and 79.5% (95% CI, 66.8% to 92.2%), respectively. No grade 4 toxicities attributable to atorvastatin were seen. In conclusion, the addition of atorvastatin to standard GVHD prophylaxis in only the recipients of MRD and MUD allo-HCT appears to be feasible and safe. The preliminary efficacy seen here warrants confirmation in randomized trials. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
19. National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report.
- Author
-
Hashmi, Shahrukh K., Bredeson, Christopher, Duarte, Rafael F., Farnia, Stephanie, Ferrey, Susan, Fitzhugh, Courtney, Flowers, Mary E.D., Gajewski, James, Gastineau, Dennis, Greenwald, Melissa, Jagasia, Madan, Martin, Patricia, Rizzo, J. Douglas, Schmit-Pokorny, Kimberly, and Majhail, Navneet S.
- Subjects
- *
BONE marrow transplantation , *MEDICAL care , *HEMATOPOIETIC stem cell transplantation , *INFORMATION technology , *ELECTRONIC health records - Abstract
Hematopoietic cell transplantation (HCT) survivors are at risk for development of late complications and require lifelong monitoring for screening and prevention of late effects. There is an increasing appreciation of the issues related to healthcare delivery and coverage faced by HCT survivors. The 2016 National Institutes of Health Blood and Marrow Transplant Late Effects Initiative included an international and broadly representative Healthcare Delivery Working Group that was tasked with identifying research gaps pertaining to healthcare delivery and to identify initiatives that may yield a better understanding of the long-term value and costs of care for HCT survivors. There is a paucity of literature in this area. Critical areas in need of research include pilot studies of novel and information technology supported models of care delivery and coverage for HCT survivors along with development and validation of instruments that capture patient-reported outcomes. Investment in infrastructure to support this research, such as linkage of databases including electronic health records and routine inclusion of endpoints that will inform analyses focused around care delivery and coverage, is required. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
20. Pretransplantation Exercise and Hematopoietic Cell Transplantation Survival: A Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0902).
- Author
-
Wingard, John R., Wood, William A., Martens, Michael, Le-Rademacher, Jennifer, Logan, Brent, Knight, Jennifer M., Jacobsen, Paul B., Jim, Heather, Majhail, Navneet S., Syrjala, Karen, Rizzo, J. Douglas, and Lee, Stephanie J.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *BONE marrow transplantation , *CLINICAL trials , *ANIMAL models in research , *NEUTROPHILS - Abstract
Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0902 evaluated whether exercise and stress management training before hematopoietic cell transplantation (HCT) improved physical and mental functioning after HCT. Neither overall survival nor other patient-reported transplantation outcomes were improved by the training intervention. In some animal studies of HCT, moderate-intensity exercise for 8 weeks before HCT has been associated with positive effects on hematopoietic progenitors, resulting in improved donor engraftment and improved survival. Accordingly, we performed a secondary analysis of data from BMT CTN 0902 to determine whether exercise engagement before HCT was associated with engraftment and survival. We found no significant associations between self-reported pre-HCT exercise levels and engraftment or survival. There was also no effect of pretransplantation exercise on either neutrophil or platelet engraftment. These findings do not support the observations in animal models but are limited by several shortcomings that do not refute the hypothesis that exercise before HCT may be beneficial. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
21. Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial.
- Author
-
Knight, Jennifer M., Syrjala, Karen L., Majhail, Navneet S., Martens, Michael, Le-Rademacher, Jennifer, Logan, Brent R., Lee, Stephanie J., Jacobsen, Paul B., Wood, William A., Jim, Heather S.L., Wingard, John R., Horowitz, Mary M., Abidi, Muneer H., Fei, Mingwei, Rawls, Laura, and Rizzo, J. Douglas
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *GRAFT versus host disease , *CLINICAL trials , *HEALTH outcome assessment , *SOCIAL status - Abstract
This secondary analysis of a large, multicenter Blood and Marrow Transplant Clinical Trials Network randomized trial assessed whether patient-reported outcomes (PROs) and socioeconomic status (SES) before hematopoietic stem cell transplantation (HCT) are associated with each other and predictive of clinical outcomes, including time to hematopoietic recovery, acute graft-versus-host disease, hospitalization days, and overall survival (OS) among 646 allogeneic and autologous HCT recipients. Pretransplantation Cancer and Treatment Distress (CTXD), Pittsburgh Sleep Quality Index (PSQI), and mental and physical component scores of the Short-Form 36 were correlated with each other and with SES variables. PROs and SES variables were further evaluated as predictors of clinical outcomes, with the PSQI and CTXD evaluated as OS predictors ( P < .01 considered significant given multiple testing). Lower attained education was associated with increased distress ( P = .002), lower income was related to worse physical functioning ( P = .005) and increased distress ( P = .008), lack of employment before transplantation was associated with worse physical functioning ( P < .01), and unmarried status was associated with worse sleep ( P = .003). In this large heterogeneous cohort of HCT recipients, although PROs and SES variables were correlated at baseline, they were not associated with any clinical outcomes. Future research should focus on HCT recipients at greater psychosocial disadvantage. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
22. Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study.
- Author
-
Sorror, Mohamed L., Logan, Brent R., Zhu, Xiaochun, Rizzo, J. Douglas, Cooke, Kenneth R., McCarthy, Philip L., Ho, Vincent T., Horowitz, Mary M., and Pasquini, Marcelo C.
- Subjects
- *
COMORBIDITY , *BONE marrow transplantation , *CELL transplantation , *HEMATOPOIETIC system - Abstract
Prospective validation of the hematopoietic cell transplantation–comorbidity index (HCT-CI) using contemporary patients treated with hematopoietic cell transplantation (HCT) across the Unites States is necessary to confirm its widespread applicability. We performed a prospective observational study including all patients (8115 recipients of allogeneic and 11,652 recipients of autologous HCT) who underwent a first HCT that was reported to the Center for International Blood and Marrow Transplant Research between 2007 and 2009. In proportional hazards models, increased HCT-CI scores were independently associated with increases in hazard ratios for nonrelapse mortality (NRM) ( P < .0001) and overall mortality ( P < .0001) among recipients of allogeneic HCT. HCT-CI scores of ≥3 were uniformly associated with higher risks for outcomes in both allogeneic and autologous HCT and in all subgroups, regardless of diagnoses, age, and conditioning intensity. Recipients of allogeneic HCT with scores of 1 and 2 who were ages < 18 years or were treated with lower intensity conditioning regimens had similar outcomes compared with those with a score of 0. Higher risks for overall mortality, but not for NRM, were observed among recipients of autologous HCT with scores of 1 and 2 versus 0. Our results confirm the validity the HCT-CI in both allogeneic and autologous HCT. The index should be used as a valid standard-of-care health measure in counseling patients for HCT, in clinical trial design, and in adjusting outcome analyses. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
23. National Survey of Hematopoietic Cell Transplantation Center Personnel, Infrastructure, and Models of Care Delivery.
- Author
-
Majhail, Navneet S., Mau, Lih-Wen, Chitphakdithai, Pintip, Payton, Tammy, Eckrich, Michael, Joffe, Steven, Lee, Stephanie J., LeMaistre, Charles F., LeRademacher, Jennifer, Loberiza, Fausto, Logan, Brent, Parsons, Susan K., Repaczki-Jones, Ramona, Robinett, Pam, Rizzo, J. Douglas, Murphy, Elizabeth, and Denzen, Ellen M.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *MEDICAL personnel , *PEDIATRICS , *MEDICAL care , *MEDICAL centers , *HEALTH surveys - Abstract
Hematopoietic cell transplantation (HCT) is a complex procedure that requires availability of adequate infrastructure, personnel, and resources at transplantation centers. We conducted a national survey of transplantation centers in the United States to obtain data on their personnel, infrastructure, and care delivery models. A 42-item web-based survey was administered to medical directors of transplantation centers in the United States that reported any allogeneic HCT to the Center for International Blood and Marrow Transplant Research in 2011. The response rate for the survey was 79% for adult programs (85 of 108 centers) and 82% for pediatric programs (54 of 66 centers). For describing results, we categorized centers into groups with similar volumes based on 2010 total HCT activity (adult centers, 9 categories; pediatric centers, 6 categories). We observed considerable variation in available resources, infrastructure, personnel, and care delivery models among adult and pediatric transplantation centers. Characteristics varied substantially among centers with comparable transplantation volumes. Transplantation centers may find these data helpful in assessing their present capacity and use them to evaluate potential resource needs for personnel, infrastructure, and care delivery and in planning for growth. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
24. Effect of Cord Blood Processing on Transplantation Outcomes after Single Myeloablative Umbilical Cord Blood Transplantation.
- Author
-
Ballen, Karen K., Logan, Brent R., Laughlin, Mary J., Wensheng He, Ambruso, Daniel R., Armitage, Susan E., Beddard, Rachel L., Bhatla, Deepika, Hwang, William Y. K., Kiss, Joseph E., Koegler, Gesine, Kurtzberg, Joanne, Nagler, Arnon, Oh, David, Petz, Lawrence D., Price, Thomas H., Quinones, Ralph R., Ratanatharathorn, Voravit, Rizzo, J. Douglas, and Sazama, Kathleen
- Subjects
- *
CORD blood transplantation , *MYELOSUPPRESSION , *HEALTH outcome assessment , *ERYTHROCYTES , *NEUTROPHILS - Abstract
Variations in cord blood manufacturing and administration are common, and the optimal practice is not known. We compared processing and banking practices at 16 public cord blood banks (CBB) in the United States and assessed transplantation outcomes on 530 single umbilical cord blood (UCB) myeloablative transplantations for hematologic malignancies facilitated by these banks. UCB banking practices were separated into 3 mutually exclusive groups based on whether processing was automated or manual, units were plasma and red blood cell reduced, or buffy coat production method or plasma reduced. Compared with the automated processing system for units, the day 28 neutrophil recovery was significantly lower after transplantation of units that were manually processed and plasma reduced (red cell replete) (odds ratio, .19; P = .001) or plasma and red cell reduced (odds ratio, .54; P = .05). Day 100 survival did not differ by CBB. However, day 100 survival was better with units that were thawed with the dextran-albumin wash method compared with the "no wash" or "dilution only" techniques (odds ratio, 1.82; P = .04). In conclusion, CBB processing has no significant effect on early (day 100) survival despite differences in kinetics of neutrophil recovery. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
25. Plerixafor and Abbreviated-Course Granulocyte Colony–Stimulating Factor for Mobilizing Hematopoietic Progenitor Cells in Light Chain Amyloidosis.
- Author
-
Dhakal, Binod, Strouse, Christopher, D'Souza, Anita, Arce-Lara, Carlos, Esselman, Jeanie, Eastwood, Daniel, Pasquini, Marcelo, Saber, Wael, Drobyski, William, Rizzo, J. Douglas, Hari, Parameswaran N., and Hamadani, Mehdi
- Subjects
- *
GRANULOCYTE-macrophage colony-stimulating factor , *PROGENITOR cells , *AMYLOIDOSIS , *ARRHYTHMIA , *MORTALITY , *STEM cells - Abstract
Cytokine-based mobilization in light chain (AL) amyloidosis is frequently complicated by fluid overload, weight gain, cardiac arrhythmias, and peri-mobilization mortality. We analyzed hematopoietic progenitor cells (HPC) mobilization outcomes in 49 consecutive AL amyloidosis patients at our institution between 2004 and 2013 with granulocyte colony–stimulating factor (G) (10 μg/kg/day) (n = 25) versus an institutional protocol to limit G exposure using plerixafor (P) (.24 mg/kg s.c. starting day 3 of G 10 μg/kg) (n = 24). G+P strategy yielded higher total CD34 + cells/kg (12.8 × 10 6 versus 6.3 × 10 6 ; P < .001) and CD34 + cells/kg collected on day 1 (10.8 × 10 6 versus 4.9 × 10 6 , P = .004) compared with the G cohort. More G+P patients collected ≥5 × 10 6 CD34 + HPCs/kg (22 versus 16, P = .02) and ≥ 10 × 10 6 CD34 + HPCs/kg (13 versus 5, P = .01). Four patients (16%) had mobilization failure with G; none with G+P. Peri-mobilization weight gain was lower with G+P strategy (median weight gain 1 versus 7 pounds, P = .009). Numbers of apheresis sessions (median, 1 versus 1, P = .52), number of hospitalization days (median, 1.1 versus 1.6, P = .52), transfusions, use of intravenous antibiotics, and cardiac arrhythmias were similar. In conclusion, our study demonstrates that upfront use of G+P as a mobilization strategy results in superior HPC collection, no mobilization failures, and less weight gain than G alone. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
26. Exercise and Stress Management Training Prior to Hematopoietic Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902.
- Author
-
Jacobsen, Paul B., Le-Rademacher, Jennifer, Jim, Heather, Syrjala, Karen, Wingard, John R., Logan, Brent, Wu, Juan, Majhail, Navneet S., Wood, William, Rizzo, J. Douglas, Geller, Nancy L., Kitko, Carrie, Faber, Edward, Abidi, Muneer H., Slater, Susan, Horowitz, Mary M., and Lee, Stephanie J.
- Subjects
- *
STRESS management , *EXERCISE , *HEMATOPOIETIC stem cell transplantation , *CLINICAL trials , *QUALITY of life , *SELF-evaluation , *HOSPITAL care - Abstract
Studies show that engaging patients in exercise and/or stress management techniques during hematopoietic cell transplantation (HCT) improves quality of life. The Blood and Marrow Transplant Clinical Trials Network tested the efficacy of training patients to engage in self-directed exercise and stress management during HCT. The study randomized 711 patients at 21 centers to receive 1 of 4 training interventions before HCT: a self-directed exercise program, a self-administered stress management program, both, or neither. Participants completed self-reported assessments at enrollment and up to 180 days after HCT. Randomization was stratified by center and transplant type. There were no differences in the primary endpoints of the Physical Component Summary and Mental Component Summary scales of the Medical Outcomes Study Short Form 36 at day +100 among the groups, based on an intention-to-treat analysis. There also were no differences in overall survival, days of hospitalization through day +100 post-HCT, or in other patient-reported outcomes, including treatment-related distress, sleep quality, pain, and nausea. Patients randomized to training in stress management reported more use of those techniques, but patients randomized to training in exercise did not report more physical activity. Although other studies have reported efficacy of more intensive interventions, brief training in an easy-to-disseminate format for either self-directed exercise or stress management was not effective in our trial. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
27. Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma.
- Author
-
Cornell, Robert Frank, Hari, Parameswaran, Zhang, Mei-Jie, Zhong, Xiabao, Thompson, Jonathan, Fenske, Timothy S., Horowitz, Mary M., Komorowski, Richard, Palmer, Jeanne, Pasquini, Marcelo C., Rizzo, J. Douglas, Saber, Wael, Thomas, Mathew, and Drobyski, William R.
- Subjects
- *
IMMUNOREGULATION , *CYCLOPHOSPHAMIDE , *STEM cell transplantation , *MULTIPLE myeloma treatment , *MULTIVARIATE analysis , *SCIENTIFIC observation - Abstract
Abstract: Engraftment syndrome (ES) is an increasingly observed and occasionally fatal complication after autologous peripheral blood stem cell transplantation (PBSCT). In this study, we demonstrate that the incidence of ES is significantly increased in patients undergoing autologous PBSCT for multiple myeloma in comparison to patients with non-Hodgkin lymphoma or Hodgkin lymphoma. Multivariate analysis revealed that age > 60 (hazard ratio [HR], 1.71; 95% confidence interval [CI], 1.12 to 2.62; P = .013) and transplantation for multiple myeloma (HR, 2.80; 95% CI, 1.60 to 4.90; P = .0003) were associated with an increased risk of this complication. When stratified for myeloma patients only, age > 60 (HR, 1.80; 95% CI, 1.13 to 2.87; P = .013) and prior treatment with both lenalidomide and bortezomib (HR, 1.83; 95% CI, 1.11 to 3.04; P = .0001) were associated with an increased incidence of ES. Conversely, lack of exposure to cyclophosphamide from either chemomobilization or as a component of the pretransplantation therapeutic regimen increased the risk of this complication (HR, 3.05; 95% CI, 1.91 to 4.87; P <.0001). These studies demonstrate that the pretransplantation exposure of multiple myeloma patients to novel immunomodulatory agents and cyclophosphamide significantly affects the subsequent risk of developing ES. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
28. Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005: Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age.
- Author
-
McCarthy, Philip L., Hahn, Theresa, Hassebroek, Anna, Bredeson, Christopher, Gajewski, James, Hale, Gregory, Isola, Luis, Lazarus, Hillard M., Lee, Stephanie J., LeMaistre, Charles F., Loberiza, Fausto, Maziarz, Richard T., Rizzo, J. Douglas, Joffe, Steven, Parsons, Susan, and Majhail, Navneet S.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *CANCER-related mortality , *LYMPHOMA treatment , *HODGKIN'S disease treatment , *TREATMENT effectiveness , *CANCER relapse - Abstract
Abstract: Autologous hematopoietic cell transplantation (auto-HCT) is performed to treat relapsed and recurrent malignant disorders and as part of initial therapy for selected malignancies. This study evaluated changes in use, techniques, and survival in a population-based cohort of 68,404 patients who underwent first auto-HCT in a US or Canadian center between 1994 and 2005 and were reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). The mean annual number of auto-HCTs performed was highest during 1996-1999 (6948), and decreased subsequently 2000-2003 (4783), owing mainly to fewer auto-HCTs done to treat breast cancer. However, the mean annual number of auto-HCTs increased from 5278 annually in 1994-1995 to 5459 annually in 2004-2005, reflecting increased use for multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma. Despite an increase in the median recipient age from 44 to 53 years, there has been a significant improvement in overall survival (OS) from 1994 to 2005 in patients with chemotherapy-sensitive relapsed non-Hodgkin lymphoma (day +100 OS, from 85% to 96%; 1-year OS, from 68% to 80%; P < .001) and chemotherapy-sensitive multiple myeloma (day +100 OS, from 96% to 98%; 1-year OS, from 83% to 92%; P < .001). This improvement in OS was most pronounced in middle-aged (>40 years) and older (>60 years) individuals. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
29. Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning
- Author
-
Weisdorf, Daniel, Zhang, Mei-Jie, Arora, Mukta, Horowitz, Mary M., Rizzo, J. Douglas, and Eapen, Mary
- Subjects
- *
LEUKEMIA treatment , *MYELOID leukemia , *GRAFT versus host disease , *DISEASE relapse , *SURVIVAL analysis (Biometry) , *HOMOGRAFTS , *TRANSPLANTATION of organs, tissues, etc. - Abstract
We studied graft-versus-host disease (GVHD) on relapse, transplant-related mortality (TRM), disease-free survival (DFS), and overall survival (OS) after allogeneic transplantation for acute myelogenous leukemia (AML) (n = 4224) and myelodysplastic syndrome (MDS) (n = 1517) in 4 groups: without GVHD, acute GVHD (aGVHD) alone, chronic GVHD (cGVHD) alone, and aGVHD + cGVHD. Examining GVHD as a time-dependent covariate, after myeloablative conditioning (MAC), cGVHD and aGVHD + cGVHD were associated with lower relapse (P < .002). TRM was higher in all GVHD groups (P < .0001); DFS and OS were lower with aGVHD ± cGVHD (P < .0001). After reduced-intensity conditioning (RIC), relapse was lower in all GVHD groups (P < .0001); TRM was increased and DFS and OS were reduced with any GVHD (P < .0001). In those surviving disease-free (≥1-year) after MAC, relapse risks were similar in all groups and TRM was higher with any GVHD (P < .0001). DFS and OS were lower with cGVHD and aGVHD + cGVHD (P < .0006). After RIC, relapse was lower (P = .009) and TRM higher (P = .002) only with aGVHD + cGVHD. DFS was similar in all groups and OS worse with aGVHD + cGVHD. After MAC, GVHD has an adverse effect on TRM with early modest augmentation of GVHD-associated graft-versus-leukemia (GVL). With RIC, GVHD-associated GVL may be important in limiting both early and late leukemia recurrence. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
30. Relationship of Race/Ethnicity and Survival after Single Umbilical Cord Blood Transplantation for Adults and Children with Leukemia and Myelodysplastic Syndromes
- Author
-
Ballen, Karen K., Klein, John P., Pedersen, Tanya L., Bhatla, Deepika, Duerst, Reggie, Kurtzberg, Joanne, Lazarus, Hillard M., LeMaistre, Charles F., McCarthy, Phillip, Mehta, Paulette, Palmer, Jeanne, Setterholm, Michelle, Wingard, John R., Joffe, Steven, Parsons, Susan K., Switzer, Galen E., Lee, Stephanie J., Rizzo, J. Douglas, and Majhail, Navneet S.
- Subjects
- *
CORD blood transplantation , *LEUKEMIA treatment , *MYELODYSPLASTIC syndromes , *BONE marrow , *MULTIVARIATE analysis , *PEDIATRIC therapy , *ADULTS - Abstract
The relationship of race/ethnicity with outcomes of umbilical cord blood transplantation (UCBT) is not well known. We analyzed the association between race/ethnicity and outcomes of unrelated single UCBT for leukemia and myelodysplastic syndromes. Our retrospective cohort study consisted of 885 adults and children (612 whites, 145 blacks, and 128 Hispanics) who received unrelated single UCBT for leukemia and myelodysplastic syndromes between 1995 and 2006 and were reported to the Center for International Blood and Marrow Transplant Research. A 5-6/6 HLA-matched unit with a total nucleated cell count infused of ≥2.5 × 107/kg was given to 40% white and 42% Hispanic, but only 21% black patients. Overall survival at 2 years was 44% for whites, 34% for blacks, and 46% for Hispanics (P = .008). In multivariate analysis adjusting for patient, disease, and treatment factors (including HLA match and cell dose), blacks had inferior overall survival (relative risk of death, 1.31; P = .02), whereas overall survival of Hispanics was similar (relative risk, 1.03; P = .81) to that of whites. For all patients, younger age, early-stage disease, use of units with higher cell dose, and performance status ≥80 were independent predictors of improved survival. Black patients and white patients infused with well-matched cords had comparable survival; similarly, black and white patients receiving units with adequate cell dose had similar survival. These results suggest that blacks have inferior survival to whites after single UCBT, but outcomes are improved when units with a higher cell dose are used. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
31. Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia
- Author
-
Majhail, Navneet S., Brazauskas, Ruta, Hassebroek, Anna, Bredeson, Christopher N., Hahn, Theresa, Hale, Gregory A., Horowitz, Mary M., Lazarus, Hillard M., Maziarz, Richard T., Wood, William A., Parsons, Susan K., Joffe, Steven, Rizzo, J. Douglas, Lee, Stephanie J., and Hayes-Lattin, Brandon M.
- Subjects
- *
HEMATOPOIETIC stem cells , *CELL transplantation , *YOUNG adults , *ACUTE myeloid leukemia , *TREATMENT of diseases in teenagers , *TRANSPLANTATION of organs, tissues, etc. in children - Abstract
Adolescents and young adults (AYAs) with cancer have not experienced improvements in survival to the same extent as children and older adults. We compared outcomes among children (<15 years), AYAs (15-40 years) and older adults (>40 years) receiving allogeneic hematopoietic cell transplant (HCT) for acute myeloid leukemia (AML). Our cohort consisted of 900 children, 2,708 AYA, and 2,728 older adult recipients of HLA-identical sibling or unrelated donor (URD) transplantation using myeloablative or reduced-intensity/nonmyeloablative conditioning. Outcomes were assessed over three time periods (1980-1988, 1989-1997, 1998-2005) for siblings and two time periods (1989-1997, 1998-2005) for URD HCT. Analyses were stratified by donor type. Results showed overall survival for AYAs using either siblings or URD improved over time. Although children had better and older adults had worse survival compared with AYAs, improvements in survival for AYAs did not lag behind those for children and older adults. After sibling donor HCT, 5-year adjusted survival for the three time periods was 40%, 48%, and 53% for children, 35%, 41%, and 42% for AYAs, and 22%, 30%, and 34% for older adults. Among URD HCT recipients, 5-year adjusted survival for the two time periods was 38% and 37% for children, 24% and 28% for AYAs, and 19% and 23% for older adults. Improvements in survival occurred because of a reduction in risk of treatment-related mortality. The risk of relapse did not change over time. Improvements in survival among AYAs undergoing allogeneic HCT for AML have paralleled those among children and older adults. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
32. Allogeneic Transplant Physician and Center Capacity in the United States
- Author
-
Majhail, Navneet S., Murphy, Elizabeth A., Omondi, Nancy A., Robinett, Pam, Gajewski, James L., LeMaistre, C.Fred, Confer, Dennis, and Rizzo, J. Douglas
- Subjects
- *
GRAFT versus host disease , *BONE marrow transplantation , *HEMATOPOIETIC stem cells , *CELL transplantation , *PHYSICIANS - Abstract
Shortage of manpower and center capacity is expected to be a major challenge to the anticipated future growth in the utilization of allogeneic hematopoietic cell transplantation (HCT) in the United States. Using data from the National Marrow Donor Program’s Transplant Center Network Renewal Survey, we describe transplant center and transplant physician capacity in the United States from 2005 to 2009. Over this 5-year period, the number of allogeneic transplants increased by 30%, bed capacity increased by 17%, and physician full-time equivalents increased by 26%. The number of related donor HCT increased by 15% and unrelated donor HCT increased by 45%. In addition to large centers, small- and medium-sized centers also made a major contribution to overall national transplant volumes for both related and unrelated donor HCT. Increase in utilization of unrelated donor HCT occurred in centers irrespective of their size. The majority of transplant centers were performing more transplantations using existing physician and bed capacity. Our study provides important descriptions of allogeneic transplant activity and capacity of U.S. centers, and our data will assist policy makers plan for the projected growth in the use of transplantation. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
33. Childhood Obesity and Outcomes after Bone Marrow Transplantation for Patients with Severe Aplastic Anemia
- Author
-
Barker, Collin C., Agovi, Manza-A., Logan, Brent, Lazarus, Hillard M., Ballen, Karen K., Gupta, Vikas, Hale, Gregory A., Frangoul, Haydar, Ho, Vincent, Rizzo, J. Douglas, and Pasquini, Marcelo C.
- Subjects
- *
CHILDHOOD obesity , *HEALTH outcome assessment , *BONE marrow transplantation , *APLASTIC anemia , *DISEASE prevalence , *HEMATOPOIETIC stem cells , *STEM cell transplantation , *BODY mass index , *PATIENTS - Abstract
The prevalence of obesity in the pediatric population has increased in the last 2 decades and represents a serious health concern, with potential impact on outcomes of hematopoietic cell transplantation (HCT). We studied the effect of weight by age-adjusted body mass index (BMI) percentile in 1,281 pediatric patients (age 2-19 years) with severe aplastic anemia who underwent HCT between 1990 and 2005. The study population was divided into 5 weight groups—underweight, risk of underweight, normal BMI range, risk of overweight, and overweight—according to age-adjusted BMI percentiles. Cox proportional hazards regression models for survival and acute graft-versus-host disease (aGVHD), performed using weight groups as the main effect and the normal BMI range (26th-75th percentile) as the baseline comparison, found higher mortality among overweight children (>95th percentile adjusted for age). Weight at transplantation did not increase the adjusted risk of grade III-IV aGVHD. The 1-year and 2-year overall survival rates were 60% and 59% for overweight children, compared with >70% in children with lower BMI at both time points (P < .001). Other significant factors associated with survival included race and region, donor type, conditioning regimens in related donor transplants, performance score, and year of transplantation. In conclusion, overweight children with aplastic anemia have worse outcomes after HCT. The impact of obesity on survival outcomes in children should be discussed during pretransplantation counseling. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
34. Factors Associated with Self-Reported Physical and Mental Health after Hematopoietic Cell Transplantation
- Author
-
Wingard, John R., Huang, I-Chan, Sobocinski, Kathleen A., Andrykowski, Michael A., Cella, David, Rizzo, J. Douglas, Brady, Marianne, Horowitz, Mary M., and Bishop, Michelle M.
- Subjects
- *
MENTAL health , *HEMATOPOIETIC stem cell transplantation , *HEMATOLOGY , *QUALITY of life , *MEDICAL genetics , *HEALTH outcome assessment - Abstract
Hematopoietic cell transplantation (HCT) is an intensive treatment for hematologic malignancies that has the potential to cure disease or prolong life, but also to impair quality of life for survivors. Earlier studies have suggested that various factors are associated with physical and mental health after HCT. In this study, we evaluated demographic and clinical factors before and after HCT and selected psychosocial factors after HCT, exploring their association with self-reported physical and mental health. We studied a cohort of 662 survivors at a median of 6.6 years after HCT. Pre-HCT demographic and clinical factors accounted for only a small amount of the variance in physical and mental health post-HCT (3% and 1%, respectively). Adding post-HCT clinical variables to the pre-HCT factors accounted for 32% and 7% of physical and mental outcomes, respectively. When both clinical and psychosocial factors were considered, better physical health post-HCT was associated with younger age, race other than white, higher current family income, currently working or being a student, less severe transplantation experience (ie, not experiencing graft-versus-host disease), fewer current comorbidities, higher Karnofsky status, less social constraint, less social support, and less trait anxiety. This multivariate model accounted for 36% of the variance in physical health, with the psychosocial variables contributing very little. When both clinical and psychosocial factors were considered, better mental health after HCT was associated with more severe transplantation experience, less social constraint, greater spiritual well being, and less trait anxiety. This multivariate model accounted for 56% of the variance in mental health, with the psychosocial factors accounting for most of the variance. These data suggest that clinical factors are explanatory for much of the post-HCT physical health reported by HCT survivors, but very little of self-perceived mental health. These observations provide insight into the identification of factors that can allow recognition of at-risk patients, as well as factors amenable to intervention. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
35. Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myelogenous Leukemia (AML) in Adults
- Author
-
Navarro, Willis H., Agovi, Manza-A., Logan, Brent R., Ballen, Karen, Bolwell, Brian J., Frangoul, Haydar, Gupta, Vikas, Hahn, Theresa, Ho, Vincent T., Juckett, Mark, Lazarus, Hillard M., Litzow, Mark R., Liesveld, Jane L., Moreb, Jan S., Marks, David I., McCarthy, Philip L., Pasquini, Marcelo C., and Rizzo, J. Douglas
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *MYELOID leukemia , *OBESITY , *BODY mass index , *HEALTH outcome assessment , *COMPARATIVE studies , *CANCER relapse , *MULTIVARIATE analysis - Abstract
The incidence of excessive adiposity is increasing worldwide, and is associated with numerous adverse health outcomes. We compared outcomes by body mass index (BMI) for adult patients with acute myelogenous leukemia (AML) who underwent autologous (auto, n = 373), related donor (RD, n = 2041), or unrelated donor (URD, n = 1801) allogeneic myeloablative hematopoietic cell transplantation (HCT) using bone marrow or peripheral blood stem cells reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) from 1995 to 2004. Four weight groups by BMI (kg/m2) were defined: underweight <18 kg/m2; normal 18-25 kg/m2; overweight >25-30 kg/m2; and obese >30 kg/m2. Multivariable analysis referenced to the normal weight group showed an increased risk of death for underweight patients in the RD group (relative risk [RR], 1.92; 95% confidence interval [CI], 1.28-2.89; P = .002), but not in the URD group. There were no other differences in outcomes among the other weight groups within the other HCT groups. Overweight and obese patients enjoyed a modest decrease in relapse incidence, although this did not translate into a survival benefit. Small numbers of patients limit the ability to better characterize the adverse outcomes seen in the underweight RD but not the underweight URD allogeneic HCT patients. Obesity alone should not be considered a barrier to HCT. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
36. Second Unrelated Donor Hematopoietic Cell Transplantation for Primary Graft Failure
- Author
-
Schriber, Jeffrey, Agovi, Manza-A., Ho, Vincent, Ballen, Karen K., Bacigalupo, Andrea, Lazarus, Hillard M., Bredeson, Christopher N., Gupta, Vikas, Maziarz, Richard T., Hale, Gregory A., Litzow, Mark R., Logan, Brent, Bornhauser, Martin, Giller, Roger H., Isola, Luis, Marks, David I., Rizzo, J. Douglas, and Pasquini, Marcelo C.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *MEDICAL care , *NEUTROPHILS , *MYELODYSPLASTIC syndromes , *LEUKEMIA , *CRYOPRESERVATION of organs, tissues, etc. , *HOMOGRAFTS - Abstract
Failure to engraft donor cells is a devastating complication after allogeneic hematopoietic cell transplantation (HCT). We describe the results of 122 patients reported to the National Marrow Donor Program between 1990 and 2005, who received a second unrelated donor HCT after failing to achieve an absolute neutrophil count of ≥500/μL without recurrent disease. Patients were transplanted for leukemia (n = 83), myelodysplastic disorders (n = 16), severe aplastic anemia (n = 20), and other diseases (n = 3). The median age was 29 years. Twenty-four patients received second grafts from a different unrelated donor. Among 98 patients who received a second graft from the same donor, 28 received products that were previously collected and cryopreserved for the first transplantation. One-year overall survival (OS) after second transplant was 11%, with 10 patients alive at last follow-up. We observed no differences between patients who received grafts from the same or different donors, or in those who received fresh or cryopreserved product. The outcomes after a second allogeneic HCT for primary graft failure are dismal. Identifying risk factors for primary graft failure can decrease the incidence of this complication. Further studies are needed to test whether early recognition and hastened procurement of alternative grafts can improve transplant outcomes for primary graft failure. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
37. Access to Hematopoietic Cell Transplantation in the United States
- Author
-
Majhail, Navneet S., Omondi, Nancy A., Denzen, Ellen, Murphy, Elizabeth A., and Rizzo, J. Douglas
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *HEALTH policy , *TRANSPLANTATION of organs, tissues, etc. , *MEDICAL literature , *MEDICAL care - Abstract
Hematopoietic cell transplantation (HCT) is a highly specialized and resource-intense medical procedure that can be associated with disparities in access to transplantation. Barriers to access to HCT are multifactorial, complex, and interrelated. Our current knowledge of specific barriers that prevent access to HCT is very limited. As the utilization of HCT increases, it is imperative that underserved populations receive the benefit of this life-saving procedure. We review the prevailing literature on access to HCT and describe research priorities for eliminating disparities in transplantation. Better understanding of these complex barriers will minimize inequities, inform health policy, guide development of interventions targeted to eliminate disparities, and continue the expansion of HCT in the future. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
38. Outcomes of Hematologic Malignancies after Unrelated Donor Hematopoietic Cell Transplantation According to Place of Residence
- Author
-
Loberiza, Fausto R., Lee, Stephanie J., Klein, John P., Hassebroek, Anna, Dehn, Jason G., Frangoul, Haydar A., Hahn, Theresa, Hale, Gregory, Lazarus, Hillard M., LeMaistre, Charles F., Maziarz, Richard T., Rizzo, J. Douglas, and Majhail, Navneet S.
- Subjects
- *
STEM cell transplantation , *HEMATOPOIETIC stem cells , *LEUKEMIA , *MYELODYSPLASTIC syndromes , *SOCIAL status , *INCOME , *RURAL geography - Abstract
Studies suggest that patients who live in rural areas may have worse clinical outcomes compared with patients living in urban areas. We studied whether place of residence (rural versus urban) is associated with clinical outcomes of patients with leukemia or myelodysplastic syndrome (MDS) who received an unrelated donor hematopoietic cell transplantation (HCT). Patients'' residential ZIP code at the time of transplant was used to determine rural or urban designation based on the Rural Urban Commuting Codes. The study included 6140 patients reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) from 121 U.S. HCT centers: 1179 (19%) came from rural areas, whereas 4961 (81%) came from urban areas. Rural and urban patients were similar in patient-, disease-, and transplant-related characteristics aside from household income and distance traveled to the HCT center. After adjusting for income and other significant patient, disease, and transplant-related variables, the risk of overall mortality between patients residing in rural and urban areas were not statistically significant (relative risk 1.01, 95% confidence intervals 0.93-1.10, P = .74). Similar outcomes were noted for treatment-related mortality (TRM), disease-free survival (DFS), and relapse. Patient''s income, derived from the U.S. Census and based on their residential ZIP code, was independently associated with outcomes. In summary, our study showed no differences in the clinical outcomes of patients from rural or urban areas after unrelated donor HCT. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
39. The Preventive Health Behaviors of Long-Term Survivors of Cancer and Hematopoietic Stem Cell Transplantation Compared with Matched Controls
- Author
-
Bishop, Michelle M., Lee, Stephanie J., Beaumont, Jennifer L., Andrykowski, Michael A., Rizzo, J. Douglas, Sobocinski, Kathleen A., and Wingard, John R.
- Subjects
- *
HEALTH behavior , *HEMATOPOIETIC stem cells , *STEM cell transplantation , *CANCER prevention , *HEALTH promotion , *BREAST cancer treatment , *CERVICAL cancer treatment , *MEDICAL screening , *BONE marrow transplantation - Abstract
Little is known about the health promotion, prevention, and disease screening behaviors of cancer survivors treated with hematopoietic cell transplantation (HCT), who undergo arduous treatment and may be at particular risk for late effects and secondary malignancies. The purposes of this study were to examine the current health and secondary prevention behaviors of long-term HCT survivors compared with matched controls without cancer, and to identify sociodemographic and clinical factors associated with appropriate preventive practices. HCT survivors (n = 662) were drawn from 40 North American transplantation centers. Peer-nominated acquaintances of survivors matched on sex, age, education, and marital status served as controls (n = 158). Data were collected a mean of 6.7 years post-HCT (range, 1.8-22.6 years). Despite a greater frequency of physical exams, the HCT survivors had similar health and screening behaviors as the matched controls. Sociodemographic factors were associated with health prevention behaviors in expected ways. Some differences between disease group and type of transplant were found, with survivors of acute leukemia less likely to report regular exercise, autologous transplant survivors more likely than allogeneic transplant survivors to report screenings for breast and cervical cancer, and allogeneic transplant survivors more likely than autologous transplant survivors to report undergoing a skin exam in the previous year. Despite higher levels of engagement with health care providers, HCT survivors had similar health behaviors as matched controls and comparable to those reported by cancer survivors who did not undergo HCT. There remains considerable room for improvement. These findings support the need for further education of both HCT survivors and health practitioners. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
40. The National Marrow Donor Program's Symposium on Patient Advocacy in Cellular Transplantation Therapy: Addressing Barriers to Hematopoietic Cell Transplantation
- Author
-
Murphy, Elizabeth A., Ferguson, Stacy Stickney, Omondi, Nancy Atieno, Getzendaner, Lisa C., Gajewski, James L., Goldstein, Gary A., Wingard, John R., Rizzo, J. Douglas, and Mahjail, Navneet S.
- Subjects
- *
STEM cell transplantation , *HEMATOPOIETIC stem cells , *GENETIC disorder treatment , *HEALTH equity , *QUALITY of life , *PATIENT advocacy , *CONFERENCES & conventions - Abstract
Although hematopoietic cell transplantation (HCT) is an effective treatment option for patients with life-threatening blood, immune system, or genetic disorders, many barriers besides a lack of suitably matched donors exist and can have an adverse impact on access and outcomes of HCT. In 2008, the National Marrow Donor Program, through its Office of Patient Advocacy, convened a diverse group of experts and transplantation survivors to identify persistent patient barriers throughout the transplantation process and to make recommendations for programs and initiatives to address these barriers, including new research opportunities. This group included transplantation physicians and other health care providers, relevant subject experts, and representatives from transplantation centers and patient advocacy organizations. Working groups were formed to identify patient barriers to HCT and to recommend and prioritize initiatives as they relate to the pretransplantation period, the early posttransplantation period, long-term survivorship, financial issues, and special populations. This report summarizes the symposium''s deliberations and recommendations to address persistent patient barriers throughout the transplantation process. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
41. A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B Cell Lymphoma: A Report from the CIBMTR
- Author
-
Lazarus, Hillard M., Zhang, Mei-Jie, Carreras, Jeanette, Hayes-Lattin, Brandon M., Ataergin, Asli Selmin, Bitran, Jacob D., Bolwell, Brian J., Freytes, César O., Gale, Robert Peter, Goldstein, Steven C., Hale, Gregory A., Inwards, David J., Klumpp, Thomas R., Marks, David I., Maziarz, Richard T., McCarthy, Philip L., Pavlovsky, Santiago, Rizzo, J. Douglas, Shea, Thomas C., and Schouten, Harry C.
- Subjects
- *
HODGKIN'S disease , *BONE marrow transplant complications , *COHORT analysis , *AUTOTRANSPLANTATION , *HEALTH outcome assessment , *MORTALITY - Abstract
We compared outcomes of 916 diffuse large B cell lymphoma (DLBCL) patients aged ≥18 years undergoing first autologous (n = 837) or myeloablative (MA) allogeneic hematopoietic cell transplant (HCT) (n = 79) between 1995 and 2003 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Median follow-up was 81 months for allogeneic HCT versus 60 months for autologous HCT. Allogeneic HCT recipients were more likely to have high-risk disease features including higher stage, more prior chemotherapy regimens, and resistant disease. Allogeneic HCT was associated with a higher 1 year treatment-related mortality (TRM) (relative risk [RR] 4.88, 95% confidence interval [CI], 3.21-7.40, P < .001), treatment failure (RR 2.06, 95% CI, 1.54-2.75, P < .001), and mortality (RR 2.75, 95% CI, 2.03-3.72, P < .001). Risk of disease progression was similar in the 2 groups (RR 1.12, 95% CI, 0.73-1.72, P = .59). In fact, for 1-year survivors, no significant differences were observed for TRM, progression, progression-free (PFS) or overall survival (OS). Increased risks of TRM and mortality were associated with older age (>50 years), lower performance score, chemoresistance, and earlier year of transplant. In a cohort of mainly high-risk DLBCL patients, upfront MA allogeneic HCT, although associated with increased early mortality, was associated with a similar risk of disease progression compared to lower risk patients receiving autologous HCT. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
42. Impending Challenges in the Hematopoietic Stem Cell Transplantation Physician Workforce
- Author
-
Gajewski, James L., LeMaistre, C. Frederick, Silver, Samuel M., Lill, Michael C., Selby, George B., Horowitz, Mary M., Rizzo, J. Douglas, Heslop, Helen E., Anasetti, Claudio, and Maziarz, Richard T.
- Subjects
- *
HEMATOPOIETIC stem cells , *BONE marrow transplantation , *MEDICAL education , *STEM cell transplantation , *TRANSPLANTATION of organs, tissues, etc. in children , *PHYSICIANS , *COMPLICATIONS from organ transplantation - Abstract
With increasing use of high dose chemotherapy with autologous and allogeneic transplants the need for the transplant physician workforce requires reassessment. The types of transplants and patients are also shifting toward transplants being done in patients with more comorbidities and more commonly these types of patients require more work effort per patient from the transplant physician. Additionally, HSCT survivors often require ongoing care at the transplant center due to the inability of the primary care workforce or the hematology/oncology workforce to absorb caring for post complex post transplant patients. The adult transplant workforce has had very few physicians join under age 40. Nearly 50% of adult transplant physicians are over age 50 whereas only 28% of pediatric transplant physicians are over age 50. By 2020, it is projected that we will need 1,264 new adult transplant physicians and 94 pediatric transplant physicians. Training time for a physician is approximately 15 years. The capping of both medical school slots and residency slots since the early ’80s is now having a very big impact on supply, but other factors are also affecting supplies such as generational differences, lifestyle expectations, and the change of the medical workforce from being mostly men. Workforce shortages are being reported for many specialities. Workforce problems are also present for nurses, pharmacists and medical technologists. So increasing use of general internists and mid-level providers may not exist as a solution. Transplant physicians must be actively engaged in the medical education process to show young medical students and residents who are not committed to another sub specialty career the excitement and challenges of a career in bone marrow transplantation, so that our field will have providers for the future. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
43. The Effect of Smoking on Allogeneic Transplant Outcomes
- Author
-
Marks, David I., Ballen, Karen, Logan, Brent R., Wang, Zhiwei, Sobocinski, Kathleen A., Bacigalupo, Andrea, Burns, Linda J., Gupta, Vikas, Ho, Vincent, McCarthy, Philip L., Ringdén, Olle, Schouten, Harry C., Seftel, Matthew, and Rizzo, J. Douglas
- Subjects
- *
HOMOGRAFTS , *PHYSIOLOGICAL effects of tobacco , *HEALTH outcome assessment , *CHRONIC myeloid leukemia , *MULTIVARIATE analysis , *ORGAN donors , *QUALITY of life , *SURVIVAL analysis (Biometry) , *LONGITUDINAL method - Abstract
Using the Center for Internaitonal Blood and Marrow Transplant Research (CIBMTR) data, we compared the transplant outcomes of patients with chronic myelogenous leukemia (CML) who were nonsmokers (NS) and past or current smokers (PCS). There were 2193 NS and 625 PCS who received matched sibling and unrelated donor allografts for CML in first chronic phase. We looked for dose effects and identified low and high dose smoking groups (>10 pack years, >1 pack per day). Outcomes were adjusted for known prognostic variables including the European Group for Blood and Marrow Transplant (EBMT) risk score. In multivariate analyses of sibling allograft recipients, relapse risk (RR) was higher (RR=1.67, P =.003) in smokers than NS, but the dose effects were not consistent. High-dose smokers experienced a 50% treatment-related mortality (TRM) versus 28% in the NS group at 5 years on univariate analysis, and the RR was 1.57 (P =.005) on multivariate analysis. Overall survival (OS) at 5 years was 68% in NS versus 62% in the low-dose smoking group versus 50% in the high-dose smoking group (P < .001). Smoking did not significantly affect outcomes in unrelated donor recipients, but numbers were smaller. High-dose smoking is associated with a reduction in OS in patients having sibling allografts for CML. A prospective study with detailed demographic, pulmonary function, and quality-of-life data would improve our understanding of this issue. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
44. Outcomes following HSCT Using Fludarabine, Busulfan, and Thymoglobulin: A Matched Comparison to Allogeneic Transplants Conditioned with Busulfan and Cyclophosphamide
- Author
-
Bredeson, Christopher N., Zhang, Mei-Jie, Agovi, Manza-A., Bacigalupo, Andrea, Bahlis, Nizar J., Ballen, Karen, Brown, Christopher, Chaudhry, M. Ahsan, Horowitz, Mary M., Kurian, Seira, Quinlan, Diana, Muehlenbien, Catherine E., Russell, James A., Savoie, Lynn, Rizzo, J. Douglas, and Stewart, Douglas A.
- Subjects
- *
CELL transplantation , *HEMATOPOIETIC stem cells , *HEALTH outcome assessment , *GRAFT versus host disease , *PRODRUGS , *SULFONATES , *FLUDARABINE - Abstract
Abstract: We have reported a lower incidence of acute graft-versus-host disease (aGVHD) with a novel conditioning regimen using low-dose rabbit antithymocyte globulin (ATG; Thymoglobulin [TG]) with fludarabine and intravenous busulfan (FluBuTG). To assess further this single-center experience, we performed a retrospective matched-pair analysis comparing outcomes of adult patients transplanted using the FluBuTG conditioning regimen with matched controls from patients reported to the CIBMTR receiving a first allogeneic hematopoietic stem cell transplant (HCT) after standard oral busulfan and cyclophosphamide (BuCy). One hundred twenty cases and 215 matched controls were available for comparison. Patients receiving FluBuTG had significantly less treatment related mortality (TRM; 12% versus 34%, P < .001) and grades II-IV aGVHD (15% versus 34%, P < .001) compared to BuCy patients. The risk of relapse was higher in the FluBuTG patients (42% versus 20%, P < .001). The risks of chronic GVHD (cGVHD) and disease free survival (DFS) were similar in the cases and controls. These results suggest that the novel regimen FluBuTG decreases the risk of aGVHD and TRM after HLA-identical sibling HSCT, but is associated with an increased risk of relapse, resulting in similar DFS. Whether these conditioning regimens may be more suitable for specific patient populations based on relapse risk requires testing in prospective randomized trials. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
45. Utility of Single versus Tandem Autotransplants for Advanced Testes/Germ Cell Cancer: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis
- Author
-
Lazarus, Hillard M., Stiff, Patrick J., Carreras, Jeanette, Logan, Brent R., Akard, Luke, Bolwell, Brian J., Childs, Richard W., Gale, Robert Peter, Klein, John P., Lill, Michael C., Pérez, Waleska S., Stadtmauer, Edward A., and Rizzo, J. Douglas
- Subjects
- *
CANCER patients , *ENDOCRINE glands , *GERMPLASM , *AUTOGRAFTS - Abstract
Abstract: Tandem autotransplants are used to treat advanced testis cancer patients but their value compared to a single autotransplant is unknown. To evaluate the results of autotransplant in relapsed testicular/germ cell cancer, data from 300 patients undergoing autotransplants 1989-2002 were reported to the Center for International Blood and Marrow Transplant Research. We compared results for those patients intended to undergo tandem autotransplant procedures (N = 102) versus patients in whom a second autotransplant was not planned (N = 198). Five-year survival probability was 35% (95% confidence interval = 25%-46%) in the planned tandem transplant cohort compared to 42% (35%-49%) in the group not planned to have a second transplant (P = .29). Probability of progression-free survival at 5 years for these cohorts was 34% (25%-44%) and 38% (31%-45%), respectively (P = .50). The planned tandem autotransplant cohort had significantly more advanced disease at diagnosis and greater likelihood of cisplatin resistance. Patients intended to receive tandem transplants had a lower treatment-related mortality at 1 year (3% versus 10%, P = .02). Using propensity score analysis the planned tandem autotransplant cohort had significantly lower treatment-related mortality (P = .044) but no different risk of relapse (P = .541) compared to the planned single transplant cohort. Tandem autotransplants for testicular cancer are associated with less treatment-related mortality than a planned single transplant, with no differences in disease-related outcomes or overall survival at 3 years. Patient selection bias for either transplant approach, however, may affect the results of this observational study; a randomized trial is needed to determine which approach, if either, is better. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
46. Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation
- Author
-
Navarro, Willis H., Loberiza, Fausto R., Bajorunaite, Ruta, van Besien, Koen, Vose, Julie M., Lazarus, Hillard M., and Rizzo, J. Douglas
- Subjects
- *
CELL transplantation , *CELLULAR therapy , *COHORT analysis - Abstract
Abstract: High-dose therapy with autologous hematopoietic cell transplantation (auto-HCT) is frequently used to improve outcomes in lymphoma. However, small studies suggest a survival disadvantage among obese patients. Using a retrospective cohort analysis, we studied the outcomes of 4681 patients undergoing auto-HCT for Hodgkin or non-Hodgkin lymphoma between 1990 and 2000 according to body mass index (BMI). Four groups categorized by BMI were compared by using Cox proportional hazards regression to adjust for other prognostic factors. A total of 1909 patients were categorized as normal weight (BMI 18-25 kg/m2), 121 as underweight (BMI <18 kg/m2), 1725 as overweight (BMI >25-30 kg/m2), and 926 as obese (BMI >30 kg/m2) at the time of HCT. Outcomes evaluated included overall survival, relapse, transplantation-related mortality (TRM), and lymphoma-free survival. TRM was similar among the normal, overweight, and obese groups; the underweight group had a higher risk of TRM (relative risk [RR], 2.46; 95% confidence interval [CI], 1.59-3.82; P < 0.0001) compared with the normal-BMI group. No differences in relapse were noted. Overall mortality was higher in the underweight group (RR, 1.48; 95% CI, 1.17-1.88; P = .001) and lower in the overweight (RR, 0.87; 95% CI, 0.79-0.96; P = .004) and obese (RR, 0.76; 95% CI, 0.67-0.86; P < .0001) groups compared with the normal-BMI group. In light of our inability to find differences in survival among overweight, obese, and normal-weight patients, obesity alone should not be viewed as a contraindication to proceeding with auto-HCT for lymphoma when it is otherwise indicated. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
47. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group Report
- Author
-
Martin, Paul J., Weisdorf, Daniel, Przepiorka, Donna, Hirschfeld, Steven, Farrell, Ann, Rizzo, J. Douglas, Foley, Ronan, Socie, Gerard, Carter, Shelly, Couriel, Daniel, Schultz, Kirk R., Flowers, Mary E.D., Filipovich, Alexandra H., Saliba, Rima, Vogelsang, Georgia B., Pavletic, Steven Z., and Lee, Stephanie J.
- Subjects
- *
CLINICAL trials , *GRAFT versus host disease , *RELIABILITY (Personality trait) , *CLINICAL medicine - Abstract
Abstract: The complexity of chronic graft-versus-host disease (GVHD) and the lack of established research methods have made it difficult to design, conduct, and analyze clinical trials involving subjects with this disease, even when promising treatment options are available. This consensus document was developed to offer an approach for overcoming these obstacles. Clinical trials in chronic GVHD should adhere to principles of good trial design and practice. Inclusion and exclusion criteria should allow as many subjects to participate as possible without compromising the interpretation of results. Pre-enrollment assessment of chronic GVHD characteristics should be standardized. The protocol should provide clear guidance about administration of study medication and other interventions. Methods of assessing response should be defined and validated in advance. Efficacy endpoints should be selected to reflect clinical benefit. Expert biostatistical support is needed to ensure the validity and reliability of trial results. The use of consistent standards in clinical trial designs to evaluate agents that have activity in pathogenic pathways could facilitate advances in the treatment of chronic GVHD. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
48. Differences in Characteristics of US Hematopoietic Stem Cell Transplantation Centers by Proportion of Racial or Ethnic Minorities
- Author
-
Schwake, Christopher J., Eapen, Mary, Lee, Stephanie J., Freytes, César O., Giralt, Sergio A., Navarro, Willis H., Rizzo, J. Douglas, van Besien, Koen, and Loberiza, Fausto R.
- Subjects
- *
STEM cells , *HEMATOPOIETIC stem cells , *PHYSICIANS , *PHYSICIAN-patient relations - Abstract
Abstract: Racial or ethnic minorities with leukemia who receive HLA-identical sibling hematopoietic stem cell transplants (HSCTs) are reported to have worse survival when compared with whites. Characteristics of US HSCT centers according to the proportion of ethnic minorities who undergo transplantation were compared to explore systematic differences among centers; the association with 100-day mortality was evaluated to determine whether center factors may explain the observed discrepant survival among ethnic minorities. One hundred sixteen US transplantation centers that performed HLA-identical sibling transplantations for leukemia were analyzed. We compared physician and health care provider staffing, transplantation unit procedure and resources, and medical center organization according to the volume procedure ratio of ethnic minorities who underwent transplantation and also according to the ratio of Hispanics who underwent transplantation. Centers that performed transplantation in a higher proportion of ethnic minorities were more likely to perform fewer transplantations per year, to have fewer devoted transplant beds, to be in an urban setting, to have a lower physician to patient volume ratio, and to follow up survivors 1 year after transplantation. Centers that performed transplantation in a higher proportion of Hispanics were more likely to perform fewer transplantations per year and to have fewer devoted transplantation beds, were less likely to perform outpatient transplantations, were more likely to be in an urban setting, and were less likely to have posttransplantation immunization protocols. Observed differences in center factors were not associated with 100-day mortality after adjustment for disease severity. Our results suggest that the inferior survival reported in ethnic minorities after HSCT may not be readily explained by center effects. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
49. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report
- Author
-
Filipovich, Alexandra H., Weisdorf, Daniel, Pavletic, Steven, Socie, Gerard, Wingard, John R., Lee, Stephanie J., Martin, Paul, Chien, Jason, Przepiorka, Donna, Couriel, Daniel, Cowen, Edward W., Dinndorf, Patricia, Farrell, Ann, Hartzman, Robert, Henslee-Downey, Jean, Jacobsohn, David, McDonald, George, Mittleman, Barbara, Rizzo, J. Douglas, and Robinson, Michael
- Subjects
- *
MEDICAL experimentation on humans , *GOVERNMENT policy , *CORNEA diseases , *CLINICAL pathology - Abstract
Abstract: This consensus document is intended to serve 3 functions. First, it standardizes the criteria for diagnosis of chronic graft-versus-host disease (GVHD). Second, it proposes a new clinical scoring system (0-3) that describes the extent and severity of chronic GVHD for each organ or site at any given time, taking functional impact into account. Third, it proposes new guidelines for global assessment of chronic GVHD severity that are based on the number of organs or sites involved and the degree of involvement in affected organs (mild, moderate, or severe). Diagnosis of chronic GVHD requires the presence of at least 1 diagnostic clinical sign of chronic GVHD (e.g., poikiloderma or esophageal web) or the presence of at least 1 distinctive manifestation (e.g., keratoconjunctivitis sicca) confirmed by pertinent biopsy or other relevant tests (e.g., Schirmer test) in the same or another organ. Furthermore, other possible diagnoses for clinical symptoms must be excluded. No time limit is set for the diagnosis of chronic GVHD. The Working Group recognized 2 main categories of GVHD, each with 2 subcategories. The acute GVHD category is defined in the absence of diagnostic or distinctive features of chronic GVHD and includes (1) classic acute GVHD occurring within 100 days after transplantation and (2) persistent, recurrent, or late acute GVHD (features of acute GVHD occurring beyond 100 days, often during withdrawal of immune suppression). The broad category of chronic GVHD includes (1) classic chronic GVHD (without features or characteristics of acute GVHD) and (2) an overlap syndrome in which diagnostic or distinctive features of chronic GVHD and acute GVHD appear together. It is currently recommended that systemic therapy be considered for patients who meet criteria for chronic GVHD of moderate to severe global severity. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
50. Tandem BMT meetings workshop descriptions
- Author
-
Horwitz, Edwin M., Lee, Stephanie J., Cutler, Corey, Antin, Joseph H., Weisdorf, Daniel, Van den Brink, Marcel, Korngold, Robert, Klein, John, Zhang, Mei-Jie, Bajorunaite, Ruta, Negrin, Robert, Waller, Edmund G., Rizzo, J. Douglas, and Socié, Gerard
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.